Viking Therapeutics, Inc. is expected to announce a dramatic decline in its earnings, with a forecasted EPS of -$0.89, representing a 178.13% drop year-over-year. This bleak financial outlook comes as the company intensifies its focus on VK2735, a promising obesity treatment in late-stage trials, amid fierce competition from industry giants like Eli Lilly and Novo Nordisk. The lack of approved products or revenues, combined with analyst ratings indicating a 'Sell' position, casts doubt on the firm's viability despite strong cash reserves to support ongoing studies. As investor confidence erodes, future success for Viking hinges on navigating regulatory processes and clinical outcomes.
“Investors will be eagerly watching for the performance of Viking Therapeutics, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$0.89, showcasing a 178.13% downward movement from the corresponding quarter of the prior year.”
“Viking Therapeutics, Inc. is currently a Zacks Rank #4 (Sell).”
“Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$2.68 per share and revenue of $0 million, indicating changes of -165.35% and 0%, respectively, compared to the previous year.”
“Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Viking Therapeutics, Inc. These recent revisions tend to reflect the evolving nature of short-term business trends.”
“We expect investors to focus on Viking Therapeutics’ VKTX progress with the development of its lead candidate, VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptors, when it reports fourth-quarter and full-year 2025 results next month.”
“We expect investors to focus on Viking Therapeutics’ VKTX progress with the development of its lead candidate, VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide receptors, when it reports fourth-quarter and full-year 2025 results next month.”
“Since the company lacks a marketed drug in its portfolio, no revenues are expected to be recorded in the upcoming quarter.”
“Factors Shaping VKTX's Q4 Results Viking Therapeutics is developing VK2735 in multiple late-stage studies as oral and subcutaneous (“SC”) formulations for the treatment of obesity.”
“VKTX is conducting two late-stage studies — VANQUISH-1 and VANQUISH-2 — which are evaluating the SC version of VK2735 over a 78-week treatment period.”
“The company is on track to complete enrollment of nearly 1,100 patients in the VANQUISH-2 study later in 2026.”
“This is likely to have brought more competitive pressure to Viking Therapeutics, given its limited resources.”
“Smaller biotech firms, like Viking Therapeutics VKTX, are also advancing GLP-1–based therapies to challenge the incumbents. Viking Therapeutics is developing its dual GIP/GLP-1 RA, VK2735, both as oral and subcutaneous formulations for the treatment of obesity.”